BR0214293A - Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo - Google Patents
Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmoInfo
- Publication number
- BR0214293A BR0214293A BR0214293-7A BR0214293A BR0214293A BR 0214293 A BR0214293 A BR 0214293A BR 0214293 A BR0214293 A BR 0214293A BR 0214293 A BR0214293 A BR 0214293A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- compound
- sub
- disease
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Abstract
"COMPOSTO E MéTODOS PARA TRATAR UM PACIENTE QUE TENHA, OU DE PREVENIR UM PACIENTE DE ADQUIRIR, UMA DOENçA OU CONDIçãO E PARA PRODUZIR UM COMPOSTO OU UM SAL OU éSTER FARMACEUTICAMENTE ACEITáVEL DO MESMO". São divulgados compostos da fórmula (1): e seus sais e ésteres farmaceuticamente aceitáveis, úteis em tratar e/ou prevenir o mal de Alzheimer e outras doenças similares, em que R~ n~, R~ c~, R~ 1~, n e R~ 20~ são aqui definidos. Estes compostos incluem inibidores da enzima betasecretase que são úteis no tratamento do mal de Alzheimer e outras doenças caracterizadas pela deposição de peptídeo A beta em um mamífero. Os compostos da invenção são úteis em composições farmacêuticas e métodos de tratamento para reduzir a formação de peptídeo A beta.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33308101P | 2001-11-19 | 2001-11-19 | |
US33400001P | 2001-11-28 | 2001-11-28 | |
US36275202P | 2002-03-08 | 2002-03-08 | |
PCT/US2002/036999 WO2003043975A1 (en) | 2001-11-19 | 2002-11-19 | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214293A true BR0214293A (pt) | 2005-04-19 |
Family
ID=27406892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0214293-7A BR0214293A (pt) | 2001-11-19 | 2002-11-19 | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo |
Country Status (11)
Country | Link |
---|---|
US (1) | US7388118B2 (pt) |
EP (1) | EP1453792B1 (pt) |
JP (1) | JP2005536448A (pt) |
AT (1) | ATE359995T1 (pt) |
AU (1) | AU2002362008A1 (pt) |
BR (1) | BR0214293A (pt) |
CA (1) | CA2467798A1 (pt) |
DE (1) | DE60219680T2 (pt) |
ES (1) | ES2284970T3 (pt) |
MX (1) | MXPA04004771A (pt) |
WO (1) | WO2003043975A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641748B1 (en) * | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
ITPD20040151A1 (it) * | 2004-06-15 | 2004-09-15 | Univ Degli Studi Trieste | Inibitori peptidomimetici di proteasi retrovirali e loro uso come antivirali |
WO2010107384A1 (en) * | 2009-03-19 | 2010-09-23 | Medivir Ab | Aspartyl protease inhibitors |
US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4864017A (en) | 1986-09-05 | 1989-09-05 | The Upjohn Company | Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert |
DE60124080T2 (de) * | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
CN1217920C (zh) * | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
JP2004532894A (ja) * | 2001-06-13 | 2004-10-28 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療するためのアミンジオール |
-
2002
- 2002-11-19 EP EP02797133A patent/EP1453792B1/en not_active Expired - Lifetime
- 2002-11-19 US US10/299,739 patent/US7388118B2/en not_active Expired - Fee Related
- 2002-11-19 DE DE60219680T patent/DE60219680T2/de not_active Expired - Fee Related
- 2002-11-19 AT AT02797133T patent/ATE359995T1/de not_active IP Right Cessation
- 2002-11-19 ES ES02797133T patent/ES2284970T3/es not_active Expired - Lifetime
- 2002-11-19 MX MXPA04004771A patent/MXPA04004771A/es active IP Right Grant
- 2002-11-19 JP JP2003545613A patent/JP2005536448A/ja active Pending
- 2002-11-19 BR BR0214293-7A patent/BR0214293A/pt not_active IP Right Cessation
- 2002-11-19 AU AU2002362008A patent/AU2002362008A1/en not_active Abandoned
- 2002-11-19 WO PCT/US2002/036999 patent/WO2003043975A1/en active IP Right Grant
- 2002-11-19 CA CA002467798A patent/CA2467798A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040039064A1 (en) | 2004-02-26 |
AU2002362008A1 (en) | 2003-06-10 |
US7388118B2 (en) | 2008-06-17 |
JP2005536448A (ja) | 2005-12-02 |
MXPA04004771A (es) | 2004-07-30 |
DE60219680D1 (de) | 2007-05-31 |
ATE359995T1 (de) | 2007-05-15 |
DE60219680T2 (de) | 2007-12-27 |
CA2467798A1 (en) | 2003-05-30 |
ES2284970T3 (es) | 2007-11-16 |
EP1453792B1 (en) | 2007-04-18 |
EP1453792A1 (en) | 2004-09-08 |
WO2003043975A1 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
MXPA04003245A (es) | Hidroxipropilaminas. | |
MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
WO2004094384A3 (en) | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease | |
WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
BR0210391A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
WO2002100818A3 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
BR0214359A (pt) | Método para tratar ou prevenir o mal de alzheimer e uma doença e para tratar um paciente que tem, ou para prevenir que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor amilóide e a produção de peptìdeo e de placa beta-amilóide e para produzir um complexo de beta-secretase, uso de um composto e, composição | |
BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo | |
BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
WO2004029019A8 (en) | Compounds for the treatment of alzheimer’s disease | |
MA27157A1 (fr) | Methode de traitement d'affections osseuses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |